Results
Barbara Ann Karmanos Cancer Institute
04/28/2026 | Press release | Archived content
IN THE NEWS: Targeting NAMPT and KRAS in Pancreatic Ductal Adenocarcinoma
April 28, 2026
CancerNetwork
Asfar Azmi, Ph.D., scientist, director of the Pancreatic Cancer Research Initiative, and Khalil Choucair, M.D., MSc, medical oncologist and member of the Thoracic Oncology Multidisciplinary Team, both members of the Molecular Therapeutics Research Program at Karmanos, presented their recent study into pancreatic ductal adenocarcinoma at the 2026 American Association for Cancer Research (AACR) Annual Meeting. It's a dual-targeting approach of nicotinamide adenine dinucleotide (NAD) metabolism via nicotinamide phosphoribosyltransferase (NAMPT) and KRAS signaling with a pan-RAS inhibitor. Dr. Azmi shares the most significant findings of this study and why this research is important.
Read the article here.
Asfar Azmi, Ph.D. Khalil Choucair, M.D., MSc
Barbara Ann Karmanos Cancer Institute published this content on April 28, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 04, 2026 at 12:07 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]